Skip to content

AOCI at other companies

Gilead Sciences logo
Gilead SciencesGILD
$78M-15.2%
Arrowhead Research logo
Arrowhead ResearchARWR
$742K-83.1%
Alkermes logo
AlkermesALKS
-$2.91M-99.9%
Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
-$31.02M-7.2%
BridgeBio Pharma logo
BridgeBio PharmaBBIO
-$8K
Rhythm Pharmaceuticals, Inc. logo
Rhythm Pharmaceuticals, Inc.RYTM

Other financials

Income statement

See full
Revenue$159.9M+43.3%
Operating income-$789.5M-5,100%
Net income-$790.2M-5,284%
EPS (diluted)-$13.43-4,377%

Balance sheet

See full
Cash & equivalents$261.5M+43.5%
Total debt$13.5M+56.4%
Total equity$242.5M+4.0%
Total assets$890.9M+29.1%

Cash flow

See full
Operating cash flow-$228.8M-11,566%
CapEx$664.0K+1,520%
Free cash flow-$229.4M-11,360%

Valuation

See full
Market cap$6.53B+152%
Enterprise value$6.28B+162%
P/S11.5×+4.6×

Profitability

See full
Operating margin-139.8%-168pp
Net margin-140.2%-169pp
FCF margin-30.3%

Returns & leverage

See full
Return on equity-335.8%-377pp
Debt / equity0.1×0.0×
Current ratio2.1×-1.1×

Where this comes from

Reported directly by Mirum Pharmaceuticals, Inc. in its filing.

Tagged under the XBRL concept us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax.

The official record: Mirum Pharmaceuticals, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Mirum Pharmaceuticals, Inc.'s aoci.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Mirum Pharmaceuticals, Inc.'s AOCI?
Mirum Pharmaceuticals, Inc. (MIRM) reported AOCI of -$28K in Q1 2026.
How has Mirum Pharmaceuticals, Inc.'s AOCI changed year-over-year?
Mirum Pharmaceuticals, Inc.'s AOCI increased by 89.1% year-over-year, from -$258K to -$28K.
What is the long-term trend for Mirum Pharmaceuticals, Inc.'s AOCI?
Over 5 years (2020 to 2025), Mirum Pharmaceuticals, Inc.'s AOCI has grown at a 33.4% compound annual growth rate (CAGR), from $83K to $351K.
What does AOCI mean?
Accumulated gains and losses bypassing the income statement — unrealized investment gains/losses, currency translation, pension adjustments, and hedge results.